Analysts are blasting MAXY on today’s CC re the company’s “gene shuffling” platform, and understandably so.
The COO (who strangely pronounces the word amino like a-MY-no) defends the platform by saying that the method of generating a follow-on-biologic does not affect immunogenicity. This is amusing because, prior to the recent mishaps with Maxy-Alpha and Maxy-Seven, MAXY had insisted that its proprietary technology virtually assured the absence of immunogenicity.
Market Data 
Markets 
AI
